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Survivin is unique for its expression in human malignancies but not in normal adult cells. It has been implicated in sensitisation
to chemotherapy and as a prognostic marker in several common cancers. Immunohistochemistry for Survivin, P53 and BCL-2
expression as well as cell proliferative index (Ki-67) and apoptosis index (TUNEL) was conducted on 52 pancreatic and 12
ampullary adenocarcinomas. Survivin was detected in the cytoplasm of carcinoma cells in 46 (88%) of pancreatic tumours. P53
and BCL-2 were detected in 54% and 12% of pancreatic tumours, respectively. Proliferative index was 26.2+10.5% and
apoptosis index was 1.38+0.69%. Prevalence of Survivin expression was signiﬁcantly higher in P53-positive than in P53-
negative cases (P=0.05) but was not associated with BCL-2 expression. Incrementally higher weighted scores of Survivin
expression were associated with increased proliferative index (P=0.001). Furthermore, there was linear correlation between
increased proliferative index and higher apoptosis index (P50.001). Surprisingly, higher scores of Survivin expression were
associated with increased apoptosis index (P=0.007). Survival characteristics were not inﬂuenced by Survivin, P53 or BCL-2
expression, apoptosis index or proliferative index. Ampullary carcinoma showed Survivin expression in 83% of cases.
However, unlike pancreatic carcinoma, there was no correlation between Survivin and P53 expression or proliferative index. In
conclusion, Survivin is expressed in the majority of pancreatic adenocarcinomas and correlates with both cellular proliferation
and apoptosis. Molecular manipulation of Survivin expression may enhance chemotherapy and radiation therapy for pancreatic
cancer.
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Adenocarcinoma of the pancreas continues to be associated with a
dismal prognosis despite substantial improvements in the surgical
technique of pancreaticoduodenectomy. Indeed, routine considera-
tion for neoadjuvant or adjuvant chemoradiation is currently
recommended (Di Magno et al, 1999). There have been enormous
advances in potential applications of molecular technology to the
treatment of pancreatic cancer (Manu et al, 2000) and, for exam-
ple, gene therapy and anti-angiogenesis therapy appear promising
modalities (Humphreys et al, 1999; van Riel et al, 1999). Detailed
understanding and careful manipulation of cellular processes, such
as programmed cell death (apoptosis) or cell proliferation, are
fundamental to the application of either chemoradiation or mole-
cular technologies to clinical practice (Fisher, 1994). Not
surprisingly, therefore, oncogenes and tumour-suppressor genes,
such as P53, as well as the underlying genetic aberrations in
pancreatic cancer have been the subject of intense research
(Schleger et al, 2000).
The inihibitor of apoptosis protein (IAP) and BCL-2 families are
critically important in the regulation of apoptosis (Jaattela, 1999).
Survivin is a recently described IAP that is unique for its expression
in a wide range of embryonic and foetal tissues but is undetectable
in terminally differentiated normal adult tissues. However, it is
prominently re-expressed in several human cancers (Ambrosini et
al, 1997). In addition to its function as an inhibitor of apoptosis,
Survivin is involved in the regulation of cellular proliferation (Li
et al, 1999) and angiogenesis in cancers (O’Connor et al, 2000).
The prognostic value of Survivin expression has been reported in
several human cancers (Altieri et al, 1999); for example, the
authors have recently reported that death from recurrent colorectal
cancer is predicted by the detection of Survivin expression using
either reverse transcriptase – polymerase chain reaction (Sarela
et al, 2000) or immunohistochemistry (Sarela et al, 2001). Further-
more, a potential therapeutic role is evident from studies
demonstrating resistance of Survivin-transfected cells to anticancer
drug-induced apoptosis (Tamm et al, 1998) and sensitisation to
chemotherapy by Survivin antisense treatment (Olie et al, 2000).
This study aimed to examine the expression and potential prog-
nostic value of Survivin, as well as P53, BCL-2 and markers of the
cellular process of apoptosis and proliferation, in pancreatic and
ampullary cancers.
MATERIALS AND METHODS
Tissue Samples
Patients who had undergone pancreaticoduodenectomy between
1994–2000 were identiﬁed and archival tissue blocks of resected
specimens were retrieved. Representative sections were stained with
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further studies were conducted on 52 adenocarcinomas of ductal
origin (excluding intra-ductal papillary mucinous neoplasms) that
were identiﬁed as originating from head, neck or uncinate process
of the pancreas and 12 carcinomas of ampulla of Vater. Pre-opera-
tive staging had been conducted using contrast enhanced dual-
phase helical CT or MR imaging, as described previously (Sheridan
et al, 1999). Pathological re-staging for the tumour (T) and lymph
node (N) categories was conducted according to the 1997 AJCC
classiﬁcation for pancreatic and ampullary cancer. Grade of differ-
entiation (Luttges et al, 2000) and status of the resection margin
(R1 if malignant cells within 1 mm of any margin) were recorded
for each case. Patient survival data were obtained from the database
of the regional cancer registry (Northern & Yorkshire Cancer
Registry & Information Service, Leeds, UK).
IMMUNOHISTOCHEMISTRY
Immunohistochemical stains were performed on parafﬁn-
embedded formalin-ﬁxed tissue sections with a StreptABCom-
plex/HRP detection system (Dako) using DAB/hydrogen peroxide
as a chromogen. The mono- and polyclonal antibodies (Mabs,
Pabs) used included Survivin (Pab; Autogen Bioclear, Wiltshire,
UK; dilution 1:200), P53 (Mab; Dako, clone DO-7; dilution
1:100), BCL-2 (Mab; Dako; dilution 1:40), and Ki-67 (Mab;
Dako; dilution 1:50). Antigen retrieval by microwave pretreatment
(265 min in 0.1 M citrate buffer pH=6 at 600 W) was performed
for all Abs except for staining with anti-BCL-2 which required
pressure cooker pretreatment (1 min in 10
73 M sodium citrate
buffer pH=6). Incubation with the primary Abs was done at room
temperature for 60 min (P53, BCL-2, Ki-67) or overnight (Survi-
vin). As a negative control, sections were processed in the
absence of primary Ab. Tissue sections from a colonic carcinoma
with known strong expression of Survivin, P53 and BCL-2 (Sarela
et al, 2001) were used as a positive control.
TUNEL
Free DNA-ends created by apoptosis were identiﬁed by TdT (term-
inal deoxyribonucleotidyl transferase)-mediated tailing with
digoxigenin-labelled nucleotides and subsequent detection via a
peroxidase-conjugated anti-digoxigenin antibody, using the Apop-
Tag kit (Intergen Company, Oxford, UK) as recommended by
the manufacturer.
Semi-quantitative assessment and statistical analysis
Proliferative and apoptotic activity was assessed by scoring the
percentage of labelled cells in at least 1000 tumour cells, as
previously described (Verbeke et al, 2000). Semi-quantitative
assessment of Survivin expression was based on the mean percen-
tage of positive tumour cells in at least ﬁve high-power ﬁelds
(6400) assigned to one of ﬁve categories: (a) 0=55%; (b)
1=5–25%; (c) 2=25–50%; (d) 3=50–75%; (e) 4=475%. The
intensity of Survivin immunostaining was scored as (a) weak=1+;
(b) moderate=2+; (c) intense=3+. The percentage of positive
tumour cells and staining intensity were multiplied to produce a
weighted score for each case (Lu et al, 1998). In tumours displaying
heterogeneous staining, the predominant pattern was considered
for scoring. Tumours with a weighted score=0 were designated as
negative; all others were considered positive. Sections were scored
as positive for P53 or BCL-2 when 410% of tumour cells
displayed nuclear or cytoplasmic immunostaining, respectively.
The software package SPSS 9.0 was used for statistical analysis.
Proliferative index and apoptosis index are reported as mean+
standard deviation. Association between Survivin expression and
various clinical and pathological variables was examined using
the w
2 test or Fisher’s exact test. The Pearson test was used to
examine linear correlation between Survivin weighted indices and
proliferative or apoptotic indices. Survival characteristics were
studied by the method of Kaplan–Meier and the Cox proportional
hazards regression model was used to examine the predictive values
of individual variables. Patients who had died of non-cancer related
causes and those who were alive at last follow-up were treated as
censored observations. P value less than 0.05 was considered statis-
tically signiﬁcant.
RESULTS
Clinical and pathological characteristics
Patients were of mean age 64 (57–71) years. Details of clinical and
various pathological variables for pancreatic cancer are shown in
Table 1. There was no signiﬁcant association between the expres-
sion of Survivin and gender, discriminators of pathological stage
or grade of pancreatic cancer. Ampullary cancers comprised T2
(three), T3 (seven) or T4 (two) tumours that were N0 (three) or
N1 (nine) and there was no stage-speciﬁc correlation with Survivin
expression (data not shown).
Expression of Survivin
Immunohistochemistry for Survivin revealed granular staining
in the cytoplasm of pancreatic carcinoma cells (Figure 1). A
few tumours showed nuclear staining in a minority of cells.
Similar features were observed in ampullary cancers. Whilst
no expression of Survivin was detected in either the stromal
cells of the tumours or in the adjacent non-neoplastic ductal
or acinar epithelium, there was strong reproducible staining of
endocrine cells within the islets of Langerhans (Figure 1).
Weighted scores for Survivin expression varied from 0–12
(Figure 2). Using a weighted score=1 for stratiﬁcation, 46
(88%) pancreatic carcinomas and 10 (83%) ampullary carcino-
mas were Survivin-positive.
Expression of P53 and BCL2
Some 28 (54%) of pancreatic cancers were P53 positive. Nuclear
immunostaining for P53 was limited to carcinoma cells and was
not observed in any stromal cells or adjacent non-neoplastic
epithelium (Figure 1). There was a signiﬁcant association between
expression of Survivin and that of P53 (Table 1). Six (12%)
pancreatic cancers were BCL-2 positive and demonstrated staining
in the cytoplasm of carcinoma cells. Inﬁltrating stromal lympho-
cytes also stained for BCL-2, irrespective of the BCL-2 status of
the cancer cells, and served as positive internal controls (Figure
1). There was no correlation between expression of Survivin and
that of BCL-2. Of ampullary cancers, eight were P53-positive and
only one was BCL-2 positive; there was no association with Survi-
vin expression.
Proliferative Index (PI)
PI for pancreatic cancers was 26.2+10.5 %. There was a signiﬁcant
positive linear correlation between PI and Survivin weighted scores
(P=0.001; Figure 3). For ampullary cancers, PI was 33.3+13.2%
and no correlation with Survivin expression was detected.
TUNEL assay
The TUNEL assay labelled apoptotic bodies. Apoptosis index (AI)
for pancreatic cancer was 1.38+0.69%. There were signiﬁcant posi-
tive linear correlations between AI and PI (P50.001; Figure 4) and
between AI and Survivin weighted score (P=0.007; Figure 5) for
pancreatic cancer. For ampullary cancer, AI was 1.59+0.62%
and, in contrast to pancreatic cancers, there was a trend (not statis-
M
o
l
e
c
u
l
a
r
a
n
d
C
e
l
l
u
l
a
r
P
a
t
h
o
l
o
g
y
Survivin in pancreatic cancers
AI Sarela et al
887
ã 2002 Cancer Research UK British Journal of Cancer (2002) 86(6), 886–892tically signiﬁcant) towards negative correlation with AI and Survi-
vin weighted scores (data not shown).
Survival characteristics
Long-term follow up data were available for 41 patients with
pancreatic cancer, none of whom had died in the post-operative
(60 days) period. The disease-speciﬁc median survival period was
20.3 (95% conﬁdence interval: 6.1–34.4) months with an actuarial
survival rate of 55.8% at 1 year and 43.0% at 2 years (Figure 6),
with a median follow-up of 13.4 (3.8–82.2) months. Only one
patient was alive at 5 years following operation. On univariate
analyses, a positive resection margin was a signiﬁcant predictor
of death due to recurrent disease. Age 460 year, presence of nodal
metastases or grade 3 differentiation also appeared to predict death
but did not achieve statistical signiﬁcance (Table 2). Survivin
expression did not predict survival at any stratifying value of the
weighted index. Similarly, a predictive value was not detected for
indices of proliferation or apoptosis. Survival analyses were not
conducted for ampullary and bile duct cancers because of the small
numbers of patients.
DISCUSSION
Expression of Survivin, of varying extent and intensity, was
detected in 88% of adenocarcinomas of the pancreas. Non-neoplas-
tic acinar parenchyma and pancreatic duct epithelium were
negative. The prevalence of Survivin expression was similar to that
reported in another smaller series of pancreatic cancers (26 cases;
77% positive) (Satoh et al, 2001). In contrast to previous observa-
tions (Adida et al, 1998b; Satoh et al, 2001), however, Survivin
immunostaining was detected in a proportion of endocrine cells
in islets of Langerhans. Using a similar polyclonal antibody, cyto-
plasmic Survivin expression has been described in 93% of
malignant melanomas (Grossman et al, 1999a), 81% of basal cell
carcinomas, 92% of cutaneous squamous cell carcinomas (Gross-
man et al, 1999b), 88% of gastric carcinomas (Okada et al,
2001) and 100% of oesophageal cancers (Beardsmore et al,
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Figure 1 Immunohistochemistry for Survivin, P53, BCL-2, Ki-67 and apoptosis (TUNEL assay) on pancreatic carcinomas. (A) Carcinomatous glands show
strong cytoplasmic expression of Survivin whereas normal duct epithelium and stromal cells are negative (2006). (B) Endocrine cells of Langerhans islets
show strong Survivin expression (1006). (C) Strong nuclear immunostaining for P53 is seen in neoplastic cells only (2006). (D) BCL-2 immunostaining is
negative in neoplastic glands. Tumour-inﬁltrating lymphocytes show strong BCL-2 expression (1006). (E) Ki-67 immunostaining reveals high proliferative
activity in neoplastic glands whereas only few positive cells are found in normal duct epithelium (2006). (F) TUNEL assay detects an apoptotic body ﬂanked
by an early apoptotic cell in a neoplastic gland (2006).
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ally lower prevalence of Survivin expression in 34% of gastric
carcinomas (Lu et al, 1998), 53–61% of colorectal carcinomas
(Kawasaki et al, 1998; Sarela et al, 2001), and 71% of breast carci-
nomas (Tanaka et al, 2000). Although Survivin was initially
described as a ubiquitous and universally present marker of human
epithelial malignancies (Ambrosini et al, 1997), such differences in
the prevalence of expression may be explained by intrinsic differ-
ences in tumour biology and higher afﬁnity of the polyclonal
antibody as compared to its monoclonal counterpart (Altieri et
al, 1999).
There was no correlation between Survivin expression and any
clinical or pathological characteristic of pancreatic adenocarcino-
ma. A similar absence of correlation has also been noted in
gastric (Lu et al, 1998), colorectal (Kawasaki et al, 1998; Sarela et
al, 2001) and breast cancers (Tanaka et al, 2000), although Survivin
expression is associated with a histologically more aggressive
phenotype of neuroblastomas (Adida et al, 1998a) and transitional
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Figure 2 Distribution of weighted scores for Survivin expression in pan-
creatic and ampullary cancers.
Table 1 Clinicopathological variables and expression of Survivin in
pancreatic cancer
No. in Survivin-
each category positive No.
Variable Category (% of variable) (% of category)
Age =560 years 27 (52) 24 (89)
460 years 25 (48) 22 (88)
Gender Male 27 (52) 23 (85)
Female 25 (48) 23 (92)
T T2 3 (6) 3 (100)
T3 49 (94) 43 (88)
N
a N0 11 (22) 10 (91)
N1 40 (78) 36 (90)
Grade 1 11 (22) 9 (82)
2 24 (47) 21 (88)
3 16 (31) 15 (93)
BCL-2 Negative 46 (88) 40 (87)
Positive 6 (12) 6 (100)
P53
b Negative 24 (46) 19 (79)
Positive 28 (54) 27 (96)
aIndeterminate for one patient.
bP=0.05. There was no signiﬁcant association
between Survivin expression and any variable other than P53.
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Figure 3 Increasing proliferative indices correlate signiﬁcantly with rising
weighted scores for Survivin expression in pancreatic cancers (P=0.001).
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Figure 4 Signiﬁcant positive correlation between proliferative and apop-
tosis indices in pancreatic cancers (P50.001).
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Figure 5 Increasing apoptosis indices correlate signiﬁcantly with rising
weighted scores for Survivin expression in pancreatic cancers (P=0.007).
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series, there was a high proportion of tumours at locally advanced
stage and this reﬂects the authors’ clinical practice and regional
referral patterns. Such a distribution of pathological stages and
the high prevalence of Survivin expression might have rendered
the power of this study insufﬁcient to demonstrate any correlation
between Survivin expression and speciﬁc pathological characteris-
tics.
Potential relationships between Survivin expression and cancer
cell proliferation or apoptosis were explored. There was signiﬁcant
positive correlation between increasing weighted indices of Survivin
expression and rising proliferative indices. A similar correlation
between Survivin expression and proliferative index has also been
reported for hepatocellular carcinomas (Ito et al, 2000). These
observations are entirely consistent with the regulated expression
of Survivin in the G2/M phase of the cell-cycle such that over-
expression may overcome an apoptotic checkpoint and favour
aberrant progression of malignant transformed cells through mito-
sis (Li et al, 1999). It is also known that anti-sense targeting of
Survivin gene expression results in inhibition of cellular prolifera-
tion (Ambrosini et al, 1998), whereas Survivin over-expression
promotes cell cycle entry with an accelerated S phase shift and
resistance to G1 arrest (Suzuki et al, 2000).
Apoptosis indices were uniformly low and there was signiﬁcant
direct correlation between proliferative and apoptotic indices in
pancreatic adenocarcinoma. Inhibition of apoptosis promotes aber-
rantly prolonged survival of mutated cells and such inhibition
appears to be a central event in malignant transformation (Bedi
et al, 1995). Furthermore, the correlation between proliferation
and apoptosis is in keeping with a well-recognised biological para-
digm, the ‘dual-signal model’, which proposes that the machineries
mediating growth and apoptosis are coupled processes (Evan and
Littlewood, 1998). In this model, activation of cell proliferation
necessarily primes the cellular apoptotic programme that, unless
countermanded by appropriate survival signals, automatically
removes the cell.
A direct correlation between increasing indices of Survivin
expression and rising apoptotic indices was also observed in
pancreatic cancer. This was surprising given the established role
of Survivin as an inhibitor of apoptosis (Ambrosini et al, 1997).
In contrast to the present observation, an association between
Survivin expression and reduced apoptotic indices has been
reported in another series of pancreatic cancer (Satoh et al,
2001) and also for colorectal (Kawasaki et al, 1998), gastric (Lu
et al, 1998), and breast cancer (Tanaka et al, 2000). In the present
study, too, there was a trend towards an association between higher
weighted scores of Survivin expression and lower apoptosis indices
in the limited number of ampullary cancers. In hepatocellular
carcinoma, however, no relation between Survivin expression and
apoptosis has been detected (Ito et al, 2000). Such variability
may be explained by tumour-speciﬁc intrinsic differences in the
complex apoptotic regulatory cascade, which includes several other
molecular regulatory factors important amongst which are P53 and
BCL-2 (Guo and Hay, 1999).
In the present study, 54% of pancreatic cancers were P53-posi-
tive and this is consistent with previous reports of 47% (Bold et al,
1999), 54% (Sinicrope et al, 1996) and 64% (Hu et al, 1998).
Although immunohistochemistry does not distinguish between
wild-type and mutated or inactivated forms of P53, it is generally
accepted that accumulated P53 represents a mutated type (Hall and
Lane, 1994). Inactivation of P53 predisposes to dysregulated prolif-
eration and aberrantly prolonged survival of mutated cells (Evan
and Littlewood, 1998) and this is reﬂected in the high frequency
of P53 inactivation in human cancers (Harris and Hollstein,
1993). There was a signiﬁcant correlation between expression of
Survivin and P53 in pancreatic cancer. Such an association has
been reported in gastric cancer (Lu et al, 1998) and it is postulated
that P53, in it’s role as a transcriptional repressor (Levine, 1997)
may negatively regulate Survivin gene expression by a mechanism
that is disrupted by P53 mutation. Expression of BCL-2 was
detected in 12% of pancreatic cancers and the sensitivity and speci-
ﬁcity of immunostaining were conﬁrmed by the prominent
expression of BCL-2 in inﬁltrating lymphocytes in all cases exam-
ined. The expression of BCL-2 in pancreatic cancers is widely
variable, with prevalence ranging from 0% (Evans et al, 2001) to
55% (Sinicrope et al, 1996).
Survival characteristics of the present cohort of patients with
pancreatic cancers compare well with other series (Yeo et al,
1998). There was no association between survival and expression
of Survivin. The relationship between Survivin expression and
aggressiveness of disease is clearly complex. For example, in color-
ectal cancer Survivin expression predicts death due to recurrent
disease speciﬁcally for patients with node-negative but not node-
positive disease (Sarela et al, 2000, 2001) and not for colorectal
cancer patients at all stages taken as a whole (Kawasaki et al,
1998). It has been previously argued that detection of Survivin
expression may independently predict a worse outcome only in
speciﬁc subgroups of patients with early stage-cancer (Sarela,
2000) and this may partly explain the absence of prognostic func-
tion for Survivin in this series of locally advanced pancreatic
adenocarcinoma. Similarly, unlike colorectal (Kawasaki et al,
1998) or breast cancer (Tanaka et al, 2000) the apoptosis index,
did not predict survival for patients with pancreatic adenocarcino-
ma.
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Table 2 Univariate analyses of clinical and pathological variables in
predicting survival following pancreaticoduodenectomy for pancreatic
adenocarcinoma
Hazard 95% CI of
Variable ratio hazard ratio P
Age (=560 year vs 460 years) 1.9 0.5–7.5 0.09
Gender (male vs female) 0.6 0.2–1.9 0.4
N category (N0 vs N1) 0.3 0.05–1.6 0.1
R category (R0 vs R1) 5.6 1.2–26.7 0.03
Grade 1 vs 2 1.1 0.3–3.9 0.9
1 vs 3 0.1 0.8–15.5 0.1
Survivin (negative vs positive) 0.3 0.06–1.8 0.2
Apoptosis index 0.5 0.2–1.4 0.2
Proliferative index 1.0 0.9–1.1 0.7
BCL2 (negative vs positive) 2.0 0.3–13.2 0.5
P53 (negative vs positive) 1.9 0.4–1.9 0.8
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Figure 6 Kaplan–Meier analysis of survival following pancreaticoduode-
nectomy for pancreatic cancer.
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in a similar high percentage (83%) of cases. However, in contrast
to pancreatic cancer, there was no correlation between Survivin
expression and P53 or proliferative index, and there was a trend
towards negative correlation between apoptosis and Survivin
expression. Although based on analysis of only a small number
of cases, these results further support the concept that adenocarci-
nom of the pancreatic head and ampullary region are separate
entities with a different prognosis.
In summary, Survivin is expressed in the majority of pancreatic
cancers and the extent of expression correlates strongly with prolif-
erative and apoptotic functions of malignant cells. These results
raise several exciting therapeutic and diagnostic possibilities. Firstly,
inhibition of Survivin expression by anti-sense treatment has been
reported to improve the effectiveness of chemotherapy (Olie et al,
2000) and might also impact on radiation therapy, especially in the
light of experimental evidence that Survivin acts as a radio-resis-
tance factor in pancreatic cancer cells (Asanuma et al, 2000).
Secondly, diagnosis of pancreatic cancer by peripheral blood-exam-
ination for anti-Survivin antibodies, as in lung or colorectal cancer
(Rohayem et al, 2000) or analysis of pancreatic duct cytology
samples, analogous to urine detection of Survivin as a diagnostic
test for bladder cancer, (Smith et al, 2001) may be possible. Finally,
the extent of Survivin expression may help predict response to
neoadjuvant or adjuvant chemotherapy, as reported for oesopha-
geal cancer (Kato et al, 2001).
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